Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia

Anesthesiology

Volumn 108, Issue 2, 2008, Pages 208-215

  Anderson, Ayuk A ^a   Brown, Rosemary L ^a   Polster, Brenda ^a,b   Pollock, Neil ^c   Stowell, Kathryn M ^a  

^a MASSEY UNIVERSITY   (New Zealand)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PALMERSTON NORTH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALCURONIUM; ALFAXALONE; ANTIBIOTIC AGENT; CALCIUM ION; CHLOROCRESOL; CYTOSINE; HALOTHANE; LIDOCAINE; NITROUS OXIDE; OXYGEN; RYANODINE RECEPTOR; SUXAMETHONIUM; THIOPENTAL; THYMINE;

ADOLESCENT; AMINO ACID SUBSTITUTION; ARTICLE; B LYMPHOCYTE; BACTERIAL MENINGITIS; CASE REPORT; CELL IMMORTALIZATION; CHEMICAL ANALYSIS; CYANOSIS; DIAGNOSTIC TEST; DNA SEQUENCE; DRUG WITHDRAWAL; EAR INFECTION; EPSTEIN BARR VIRUS; FAMILY ASSESSMENT; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HAPLOTYPE; HEART VENTRICLE FIBRILLATION; HUMAN; IN VITRO STUDY; LEG PAIN; LYMPHOBLASTOID CELL; MALIGNANT HYPERTHERMIA; MASTOIDECTOMY; MORTALITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RIGIDITY; SCHOOL CHILD; SIDE EFFECT; SKELETAL MUSCLE; SKIN FLAP;

EID: 38549167375     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/01.anes.0000299431.81267.3e     Document Type: Article

References (40)

1. 2+) release channels? Trends Cardiovasc Med 2002; 12:189-97
2. Jurkat-Rott K, McCarthy T, Lehmann-Horn FT: Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 2000; 23:4-17
3. 2+ release channels. Am J Med 1998; 104:470-86
4. Denborough M, Lovell R: Anaesthetic deaths in a family. Lancet 1960; 2:45
5. Wappler F: Malignant hyperthermia. Eur J Anaesthesiol 2001; 18:632-52
6. MacLennan DH, Duff C, Zorzato F, Fujii J, Phillips M, Korneluk RG, Frodis W, Britt BA, Worton RG: Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990; 343:559-61
7. Britt BA, Kalow W: Malignant hyperthermia: A statistical review. Can Anaesth Soc J 1970; 17:293-315
8. Ording H: Incidence of malignant hyperthermia in Denmark. Anesth Analg 1985; 64:700-4
9. Hopkins PM: Malignant hyperthermia: Advances in clinical management and diagnosis. Br J Anaesth 2000; 85:118-28
10. Monnier N, Krivosic-Horber R, Payen JF, Kozak-Ribbens G, Nivoche Y, Adnet P, Reyford H, Lunardi J: Presence of two different genetic traits in malignant hyperthermia families: Implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. ANESTHESIOLOGY 2002; 97:1067-74
11. Monnier N, Kozak-Ribbens G, Krivosic-Horber R, Nivoche Y, Qi D, Kraev N, Loke J, Sharma P, Tegazzin V, Figarella-Branger D, Romero N, Mezin P, Bendahan D, Payen JF, Depret T, Maclennan DH, Lunardi J: Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility. Hum Mutat 2005; 26:413-25
12. Sambuughin N, Holley H, Muldoon S, Brandom BW, de Bantel AM, Tobin JR, Nelson TE, Goldfarb LG: Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the North American population. ANESTHESIOLOGY 2005; 102:515-21
13. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P: Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006; 27:977-89
14. Girard T, Cavagna D, Padovan E, Spagnoli G, Urwyler A, Zorzato F, Treves S: B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators. J Biol Chem 2001; 276:48077-82
15. Sei Y, Brandom BW, Bina S, Hosoi E, Gallagher KL, Wyre HW, Pudimat PA, Holman SJ, Venzon DJ, Daly JW, Muldoon S: Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes. ANESTHESIOLOGY 2002; 97:1052-8
16. Sei Y, Gallagher KL, Basile AS: Skeletal muscle type ryanodine receptor is involved in calcium signaling in human B lymphocytes. J Biol Chem 1999; 274:5995-6002
17. Tilgen N, Zorzato F, Halliger-Keller B, Muntoni F, Sewry C, Palmucci LM, Schneider C, Hauser E, Lehmann-Horn F, Muller CR, Treves S: Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: Association with central core disease and alteration of calcium homeostasis. Hum Mol Genet 2001; 10:2879-87
18. Herrmann-Frank A, Richter M, Sarkozi S, Mohr U, Lehmann-Horn F: 4-Chloro-m-cresol, a potent and specific activator of the skeletal muscle ryanodine receptor. Biochim Biophys Acta 1996; 1289:31-40
19. Goelz SE, Hamilton SR, Vogelstein B: Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun 1985; 130:118-26
20. Davis M, Brown R, Dickson A, Horton H, James D, Laing N, Marston R, Norgate M, Perlman D, Pollock N, Stowell K: Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees. Br J Anaesth 2002; 88:508-15
21. Brown RL, Pollock AN, Couchman KG, Hodges M, Waaka R, Lynch P, McCarthy TV, Stowell KM: A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree. Hum Mol Genet 2000; 9:1515-24
22. Schutz E, von Ahsen N: Spreadsheet software for thermodynamic melting point prediction of oligonucleotide hybridization with and without mismatches. Biotechniques 1999; 27:1218-22, 1224
23. von Ahsen N, Oellerich M, Armstrong VW, Schutz E: Application of a thermodynamic nearest-neighbor model to estimate nucleic acid stability and optimize probe design: Prediction of melting points of multiple mutations of apolipoprotein B-3500 and factor V with a hybridization probe genotyping assay on the lightcycler. Clin Chem 1999; 45:2094-101
24. Gyapay G, Morisette JM, Vignal A, Dib C, Fizames C, Millaeau P, Marc P: The 1993-94 Genethon human genetic linkage map. Nat Genet 1994; 7:246-339
25. Weissenbach J, Gyapay G, Dib C, Vignal. A, Moissette J, Millasseau P, Vaysseix G, Lathrop M: A second-generation linkage map of the human genome. Nature 1992; 359:794-801
26. Weber JL, May PE: Abundant class of human polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet 1989; 44:388-96
27. Gillard EF, Otsu K, Fujii J, Duff C, de Leon S, Khanna VK, Britt BA, Worton RG, MacLennan DH: Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (ryr1) gene in individuals with malignant hyperthermia. Genomics 1992; 13:1247-54
28. Neitzel H: A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet 1986; 73:320-6
29. 2+ release. Biochem J 2004; 382:557-64
30. Tintinger GR, Theron AJ, Steel HC, Anderson R: Accelerated calcium influx and hyperactivation of neutrophils in chronic granulomatous disease. Clin Exp Immunol 2001; 123:254-63
31. Ducreux S, Zorzato F, Ferreiro A, Jungbluth H, Muntoni F, Monnier N, Muller CR, Treves S: Functional properties of ryanodine receptors carrying three amino acid substitutions identified in patients affected by multi-minicore disease and central core disease, expressed in immortalized lymphocytes. Biochem J 2006; 395:259-66
32. Lytton J, Westlin M, Hanley MR: Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biol Chem 1991; 266:17067-71
33. Takemura H, Hughes AR, Thastrup O, Putney JW Jr: Activation of calcium entry by the tumor promoter thapsigargin in parotid acinar cells: Evidence that an intracellular calcium pool and not an inositol phosphate regulates calcium fluxes at the plasma membrane. J Biol Chem 1989; 264:12266-71
34. Censier K, Urwyler A, Zorzato F, Treves S: Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia- susceptible and normal individuals: Effect of overexpression of recombinant wild-type and arg163cys mutated ryanodine receptors. J Clin Invest 1998; 101:1233-42
35. Endo M, Yagi S, Ishizuka T, Horiuti K, Koga Y, Amaha K: Changes in the calcium induced release mechanism in the sarcoplasmic reticulum of the muscle from a patient with malignant hyperthermia. Biomed Res 1983; 4:83-9
36. Wehner M, Rueffert H, Koenig F, Neuhaus J, Olthoff D: Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 thr2206met (C6617T) mutation. Clin Genet 2002; 62:135-46
37. Urwyler A, Deufel T, McCarthy T, West S: Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86:283-7
38. Fagerlund TH, Ording H, Bendixen D, Islander G, Ranklev Twetman E, Berg K: Discordance between malignant hyperthermia susceptibility and RYR1 mutation C1840T in two Scandinavian MH families exhibiting this mutation. Clin Genet 1997; 52:416-21
39. MacLennan DH: Discordance between phenotype and genotype in malignant hyperthermia. Curr Opin Neurol 1995; 8:397-401
40. Robinson RL, Anetseder MJ, Brancadoro V, van Broekhoven C, Carsana A, Censier K, Fortunato G, Girard T, Heytens L, Hopkins PM, Jurkat-Rott K, Klinger W, Kozak-Ribbens G, Krivosic R, Monnier N, Nivoche Y, Olthoff D, Rueffert H, Sorrentino V, Tegazzin V, Mueller CR: Recent advances in the diagnosis of malignant hyperthermia susceptibility: How confident can we be of genetic testing? Eur J Hum Genet 2003; 11:342-8